Analysts Set Expectations for Delcath Systems Q1 Earnings

Delcath Systems, Inc. (NASDAQ:DCTH) – Research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Delcath Systems in a research report issued on Thursday, August 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $0.09 per share for the quarter, down from their prior forecast of $0.13. HC Wainwright has a “Buy” rating and a $31.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.27 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $2.02 EPS and FY2029 earnings at $2.55 EPS.

Several other research firms have also recently weighed in on DCTH. Stephens restated an “overweight” rating and set a $25.00 target price on shares of Delcath Systems in a research note on Monday, June 23rd. Wall Street Zen cut Delcath Systems from a “buy” rating to a “hold” rating in a research note on Sunday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Delcath Systems has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH opened at $10.01 on Friday. The company has a market capitalization of $350.15 million, a P/E ratio of 200.20 and a beta of 0.82. Delcath Systems has a 1 year low of $7.17 and a 1 year high of $18.23. The business’s 50 day simple moving average is $12.96 and its 200 day simple moving average is $13.60.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.05. The business had revenue of $24.16 million for the quarter, compared to the consensus estimate of $22.84 million. Delcath Systems had a return on equity of 6.91% and a net margin of 3.18%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. USA Financial Formulas bought a new position in Delcath Systems during the 2nd quarter worth $25,000. Quarry LP bought a new position in Delcath Systems during the 4th quarter worth $34,000. Inlight Wealth Management LLC bought a new position in Delcath Systems during the 1st quarter worth $85,000. Police & Firemen s Retirement System of New Jersey bought a new position in Delcath Systems during the 2nd quarter worth $97,000. Finally, Graham Capital Management L.P. bought a new position in Delcath Systems during the 4th quarter worth $123,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.